-
World No.2 Rybakina retires from Cincinnati clash with Swiatek
-
Key European leaders demand Israel halt West Bank settlement project
-
'I heard you missed me': Melania Trump jokes about month out of spotlight
-
McIlroy bounces back to share BMW Championship lead
-
Amazon Prime Video to invest $2 bn in Latin America productions
-
Cobolli fueled by candy in sweet defeat of Paul
-
Panama Canal to reduce shipping over El Nino-fueled drought
-
Jailed Pakistan ex-PM Khan moved to hospital on court order: party
-
Maradona trial on hold over possible medical evidence mix-up
-
Pogacar eyes 'missing' piece ahead of Vuelta return
-
'Green dilemma': China's solar boom hurt birds, says study
-
US, Canada 'very close' to trade deal, Ottawa says, as details emerge
-
Pegula hangs on to dispatch Anisimova, reach Cincinnati semi-finals
-
Ronaldinho returns in search of 'beautiful' 300th goal
-
US charges woman with IS-inspired plot to blow up New York State Capitol
-
US pushes allies, China to back Trump's economic war on Iran
-
What a record-breaking El Nino could mean for the world
-
Former NBA MVP Harden reportedly set to return to Cavaliers
-
Duplantis edges Karalis to win Lausanne Diamond League pole vault
-
Brook makes Pakistan pay for drop as England dominate first Test
-
Alcaraz to return for US Open title defence
-
MemeCore Arrives on Nasdaq Through $1 Billion Landmark Treasury Transaction
-
China's rapid solar expansion hurt bird diversity: study
-
First US deportees land in Liberia
-
President Paul Biya back in Cameroon after 73 days away
-
US, Canada resume talks to finalize trade deal as details emerge
-
Newcastle boss Jaissle unfazed by lack of respect
-
Europe heatwaves scorch 80 million with 40 C heat: AFP analysis
-
US Open purse to top $100 mn as Grand Slams form player council
-
Carrick insists Man Utd will make more signings after quiet transfer window
-
Hull aim to silence critics after unexpected promotion to Premier League
-
US warns allies, China to back economic war on Iran
-
Pakistan hit back against England after Cox and Root fifties
-
Manifesto defends Germany's iconic Bauhaus against 'populist attacks'
-
Walmart reports mixed results as gas prices drag on US sales growth
-
Kenya's Kipyegon ends season with hamstring injury
-
Wang downs Sindhu to break Indian hearts at badminton worlds
-
Nord Stream bomb suspect arrested while working on movie about attack: media
-
As Europe's rivers recede, shippers scramble to limit damage
-
German football fans plan widespread VAR protests
-
Alonso won't confirm Fernandez will remain at Chelsea after Man City link
-
Scorching summer triggers record rockfalls in Alps, scientist says
-
Milky Way's fastest star discovered spinning around black hole
-
Newly-crowned European champ Werro turns focus on 800m record
-
Kanye West planned concerts trigger frenzy in Russia
-
Hamilton 'fittest ever' as he chases eighth F1 title
-
Hungary music festival basks in post-Orban freedom
-
Stocks retreat as bond yield fears persist, oil rises
-
Vatican says 'serious concerns' over Israel-Lebanon deal implementation
-
ARKBRIDGE’s David Mali Highlights AI-Driven Risk Management at the Finance Magnates London Summit
Revive Therapeutics Announces Proposed Shares for Debt Settlement
TORONTO, ON / ACCESS Newswire / August 19, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, announces a proposed debt settlement pursuant to which the Company intends to issue up to 1,221,516 common shares in the capital of the Company (the "Settlement Shares") at a deemed price of $0.05 per Settlement Share to settle an aggregate of $61,061 in outstanding trade payables owing to two arm's length creditors of the Company (the "Debt Settlement").
The Settlement Shares will be issued in accordance with the policies of the Canadian Securities Exchange (the "CSE"). All Settlement Shares issued pursuant to the Debt Settlement will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities laws. Completion of the Debt Settlement remains subject to certain conditions, including receipt of all necessary regulatory approvals, including approval of the CSE.
The Debt Settlement is expected to close no earlier than five business days from the date of this news release and remains subject to CSE acceptance
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness. For more information, visit www.revivethera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1-888-901-0036
Email: [email protected]
Website: www.revivethera.com
SOURCE: Revive Therapeutics Ltd.
View the original press release on ACCESS Newswire
E.Hall--AT